175 related articles for article (PubMed ID: 23541946)
1. Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells.
Qiao Z; Ren S; Li W; Wang X; He M; Guo Y; Sun L; He Y; Ge Y; Yu Q
Biochem Biophys Res Commun; 2013 Apr; 434(1):95-101. PubMed ID: 23541946
[TBL] [Abstract][Full Text] [Related]
2. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer.
Arnold NB; Arkus N; Gunn J; Korc M
Clin Cancer Res; 2007 Jan; 13(1):18-26. PubMed ID: 17200334
[TBL] [Abstract][Full Text] [Related]
3. Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer.
Wang G; He J; Zhao J; Yun W; Xie C; Taub JW; Azmi A; Mohammad RM; Dong Y; Kong W; Guo Y; Ge Y
PLoS One; 2012; 7(12):e52095. PubMed ID: 23251689
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effect of chidamide on the growth of human adenoid cystic carcinoma cells.
Yang S; Nan P; Li C; Lin F; Li H; Wang T; Zhou C; Zhang X; Meng X; Qian H; Wang H; Dong M
Biomed Pharmacother; 2018 Mar; 99():608-614. PubMed ID: 29710459
[TBL] [Abstract][Full Text] [Related]
5. Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer.
Zhao B; He T
Oncol Rep; 2015 Jan; 33(1):304-10. PubMed ID: 25384499
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitor MGCD0103 synergizes with gemcitabine in human pancreatic cells.
Sung V; Richard N; Brady H; Maier A; Kelter G; Heise C
Cancer Sci; 2011 Jun; 102(6):1201-7. PubMed ID: 21375679
[TBL] [Abstract][Full Text] [Related]
7. Chidamide Inhibits Aerobic Metabolism to Induce Pancreatic Cancer Cell Growth Arrest by Promoting Mcl-1 Degradation.
He M; Qiao Z; Wang Y; Kuai Q; Li C; Wang Y; Jiang X; Wang X; Li W; He M; Ren S; Yu Q
PLoS One; 2016; 11(11):e0166896. PubMed ID: 27875574
[TBL] [Abstract][Full Text] [Related]
8. Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model.
Brandes F; Schmidt K; Wagner C; Redekopf J; Schlitt HJ; Geissler EK; Lang SA
BMC Cancer; 2015 Feb; 15():71. PubMed ID: 25884642
[TBL] [Abstract][Full Text] [Related]
9. Chidamide and 5-flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice.
Liu L; Qiu S; Liu Y; Liu Z; Zheng Y; Su X; Chen B; Chen H
Neoplasma; 2016; 63(2):193-200. PubMed ID: 26774139
[TBL] [Abstract][Full Text] [Related]
10. The Histone Deacetylase Inhibitor Valproic Acid Sensitizes Gemcitabine-Induced Cytotoxicity in Gemcitabine-Resistant Pancreatic Cancer Cells Possibly Through Inhibition of the DNA Repair Protein Gamma-H2AX.
Wang Y; Kuramitsu Y; Kitagawa T; Tokuda K; Baron B; Akada J; Nakamura K
Target Oncol; 2015 Dec; 10(4):575-81. PubMed ID: 25940934
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells.
Jacob DA; Bahra M; Langrehr JM; Boas-Knoop S; Stefaniak R; Davis J; Schumacher G; Lippert S; Neumann UP
J Gastroenterol Hepatol; 2007 May; 22(5):738-48. PubMed ID: 17444865
[TBL] [Abstract][Full Text] [Related]
12. Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in Non-Small-Cell lung cancer cells.
Zhou Y; Pan DS; Shan S; Zhu JZ; Zhang K; Yue XP; Nie LP; Wan J; Lu XP; Zhang W; Ning ZQ
Biomed Pharmacother; 2014 May; 68(4):483-91. PubMed ID: 24721323
[TBL] [Abstract][Full Text] [Related]
13. Preclinical and Clinical Studies of Chidamide (CS055/HBI-8000), An Orally Available Subtype-selective HDAC Inhibitor for Cancer Therapy.
Gao S; Li X; Zang J; Xu W; Zhang Y
Anticancer Agents Med Chem; 2017; 17(6):802-812. PubMed ID: 27592546
[TBL] [Abstract][Full Text] [Related]
14. Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors.
Haefner M; Bluethner T; Niederhagen M; Moebius C; Wittekind C; Mossner J; Caca K; Wiedmann M
World J Gastroenterol; 2008 Jun; 14(23):3681-92. PubMed ID: 18595135
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-α on pancreatic cancer cells.
Iwahashi S; Shimada M; Utsunomiya T; Morine Y; Imura S; Ikemoto T; Mori H; Hanaoka J; Sugimoto K; Saito Y
Int J Clin Oncol; 2011 Dec; 16(6):671-8. PubMed ID: 21556798
[TBL] [Abstract][Full Text] [Related]
16. Effects and mechanisms of the combination of suberoylanilide hydroxamic acid and bortezomib on the anticancer property of gemcitabine in pancreatic cancer.
Lee JK; Ryu JK; Yang KY; Woo SM; Park JK; Yoon WJ; Lee SH; Jeong KS; Kim YT; Yoon YB
Pancreas; 2011 Aug; 40(6):966-73. PubMed ID: 21487323
[TBL] [Abstract][Full Text] [Related]
17. Combined targeting of histone deacetylases and hedgehog signaling enhances cytoxicity in pancreatic cancer.
Chun SG; Zhou W; Yee NS
Cancer Biol Ther; 2009 Jul; 8(14):1328-39. PubMed ID: 19421011
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA damage and abrogation of ribonucleotide reductase induction by gemcitabine.
Liu S; Ge Y; Wang T; Edwards H; Ren Q; Jiang Y; Quan C; Wang G
Oncol Rep; 2017 Jun; 37(6):3377-3386. PubMed ID: 28440428
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors.
Chan E; Chiorean EG; O'Dwyer PJ; Gabrail NY; Alcindor T; Potvin D; Chao R; Hurwitz H
Cancer Chemother Pharmacol; 2018 Feb; 81(2):355-364. PubMed ID: 29238851
[TBL] [Abstract][Full Text] [Related]
20. Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells.
Thoennissen NH; Iwanski GB; Doan NB; Okamoto R; Lin P; Abbassi S; Song JH; Yin D; Toh M; Xie WD; Said JW; Koeffler HP
Cancer Res; 2009 Jul; 69(14):5876-84. PubMed ID: 19605406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]